Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
The latest announcement is out from Cadrenal Therapeutics, Inc. ( (CVKD) ).
On September 12, 2025, Cadrenal Therapeutics, Inc. acquired assets from eXIthera Pharmaceuticals, including investigational intravenous and oral Factor XIa inhibitors, significantly enhancing its pipeline in the anticoagulation market. The acquisition positions Cadrenal to deliver differentiated therapeutics across cardiovascular thrombotic risk, with potential milestone payments to eXIthera up to $15 million and royalties on global sales, marking a strategic move to address large and underserved segments of the $38 billion global anticoagulation market.
The most recent analyst rating on (CVKD) stock is a Buy with a $45.00 price target. To see the full list of analyst forecasts on Cadrenal Therapeutics, Inc. stock, see the CVKD Stock Forecast page.
Spark’s Take on CVKD Stock
According to Spark, TipRanks’ AI Analyst, CVKD is a Underperform.
The overall score reflects significant financial challenges, including ongoing losses and no revenue generation, which weigh heavily on the company’s outlook. Technical indicators suggest limited momentum, while valuation metrics highlight difficulties in assessing the stock’s fair value. Despite a positive corporate development with the appointment of a new Chief Medical Officer, the fundamental financial weaknesses remain the dominant concern.
To see Spark’s full report on CVKD stock, click here.
More about Cadrenal Therapeutics, Inc.
Cadrenal Therapeutics, Inc. is a biopharmaceutical company focused on developing transformative therapeutics to address gaps in anticoagulation therapy. Its lead investigational product is tecarfarin, an oral Vitamin K antagonist anticoagulant designed to prevent heart attacks, strokes, and deaths due to blood clots in patients requiring chronic anticoagulation. The company aims to reduce the clinical complexities of managing Vitamin K antagonists, particularly where direct-acting oral anticoagulants are inadequate.
Average Trading Volume: 30,220
Technical Sentiment Signal: Sell
Current Market Cap: $26.92M
For an in-depth examination of CVKD stock, go to TipRanks’ Overview page.